- Completes first phase in committed investment of US$ 150M (> INR 1000 Cr)
- Sri KT Rama Rao, Hon'ble Minister for Industry & Commerce
and IT, Government of Telangana inaugurates the facility
HYDERABAD, India, Aug. 15, 2020 /PRNewswire/ -- Sai Life
Sciences, one of India's fastest
growing Contract Development & Manufacturing Organizations
(CDMOs), today announced the inauguration of its new Research and
Technology (R&T) Centre in Hyderabad,
India. Sri K T Rama Rao, Hon'ble Minister for
Industry & Commerce and IT, Government of Telangana formally
inaugurated the facility in the presence of other dignitaries.
Speaking on the occasion, Sri KT Rama Rao said, "I'm very happy
that the esteemed leadership of Sai Life sciences has considered
Telangana for setting up their new R&D centre. Life Sciences is
one of the key focus sectors for the Government of Telangana.
Hyderabad serves more than 1000
global innovators in their vision to develop innovative and
affordable medicines for the world. I sincerely congratulate the
entire team of Sai Life Sciences, not only for the new Research
& Technology Centre but, also for their work towards the
development and manufacturing of new life saving medicines."
Built with an aspiration to achieve the best global benchmarks
in lab infrastructure, the new R&T facility has several
unique aspects such as intelligent & ergonomic lab design to
enhance safety and productivity, advanced automation for seamless
data capture during process development, lean & 5S approach to
enhance productivity and collaborative workspaces for engendering
innovation.
Making the announcement, Krishna
Kanumuri, CEO & Managing Director of Sai Life
Sciences said, "Our philosophy behind building this new facility
was to go beyond what the norm is in India and to create what our global innovator
partners expect in their inhouse capabilities." He further added,
"We are an example of what is possible in Hyderabad's rich life sciences ecosystem.
Today, as we build world class R&D capabilities and invest in
nurturing talent with deep domain expertise, I can unhesitatingly
say, Hyderabad is truly a city
where pharma dreams are made."
The new 83,000 sq.ft. (7700 sq.m.) facility houses
state-of-the-art research capabilities and advanced technology
platforms, augmenting the company's capabilities in providing
superior scientific solutions to its pharma and biotech innovator
customers globally. It has 24 chemistry labs with 250 fume hoods,
analytical labs, fully equipped technology suite and a dedicated
process safety lab.
Sai Life Sciences began a process of organizational
transformation in 2019 reinventing itself as a new generation
global CDMO. Through this initiative, named Sai Nxt,
the company is investing over US$
150M (> INR 1000 Cr) to expand and upgrade its R&D
and manufacturing facilities, induct top-notch global scientific
and leadership talent, strengthen automation and data systems, and
above all raise the bar for safety, quality and customer focus.
About Sai Life Sciences
Sai Life Sciences is a
full-service CDMO driven by a vision to support the launch of 25
new medicines by 2025. It works with innovator pharma and
biotech companies globally, accelerating the discovery, development
and manufacture of complex small molecules. A pure-play CDMO, Sai
Life Sciences has served a diverse set of NCE development programs,
consistently delivering value based on its quality and
responsiveness. Today, it works with 7 of the top 10 large pharma
companies, as well as several small and mid-sized pharma &
biotech companies. Sai Life Sciences is privately held and backed
by global investors, TPG Capital and HBM Healthcare Investments.
https://www.sailife.com/
Photo:
https://mma.prnewswire.com/media/1228693/Sai_Life_Sciences.jpg
Photo:
https://mma.prnewswire.com/media/1228696/Sci_Life_Sciences_Centre.jpg
Logo:
https://mma.prnewswire.com/media/1044186/Sai_Life_Sciences_Logo.jpg